Oncoteq is a clinical stage biotech, that leverages AI to unlock the value of exciting oncology assets
What we do
Oncoteq is a clinical stage biotech company leveraging AI to optimise and de-risk oncology assets. The pipeline is composed of three attractive assets in areas of high unmet need and compelling reason to believe established pre-clinically.
The phase 1/1b clinical trials are designed to deliver early proof of concept and differentiation against standard of care. Development plans and scientific and translational decision making has been optimised with industry leading AI platform of Innoplexus AG.
Pioneering innovation in drug development
Oncoteq is pioneering a new approach involving AI in decision making to achieve optimised, de-risked and accelerated clinical development.
Cureteq est.
Nov 2021
Privately held
10+ Employees
Strategic partners
Innoplexus
Office in Cham
Portfolio company
Oncoteq est. Apr 2022
Shortcuts to Management, Board of Directors & Scientific Advisors
Management
Swiss headquartered Oncoteq boasts a skilled and dedicated team of professionals. The team represents a broad range of experience from large pharma to biotech and in executive leadership roles across …
Board of Directors
The Board of Directors of Oncoteq is currently comprised of Directors from the founding company, Cureteq AG.
Advisors
Oncoteq’s advisors are accomplished executives with extensive and deep experience across scientific, translational, financial and commercial aspects of drug development